Search Results - "TJEERD BARF" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis

by van der Wel, Tom, Hilhorst, Riet, den Dulk, Hans, van den Hooven, Tim, Prins, Nienke M., Wijnakker, Joost A. P. M., Florea, Bogdan I., Lenselink, Eelke B., van Westen, Gerard J. P., Ruijtenbeek, Rob, Overkleeft, Herman S., Kaptein, Allard, Barf, Tjeerd, van der Stelt, Mario
Published in Nature communications (25.06.2020)

Get full text

Journal Article

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

by Kaptein, Allard, de Bruin, Gerjan, Emmelot-van Hoek, Maaike, van de Kar, Bas, de Jong, Anouk, Gulrajani, Michael, Demont, Dennis, Covey, Todd, Mittag, Diana, Barf, Tjeerd
Published in Blood (29.11.2018)

Get full text

Journal Article

N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors

N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors

by Barf, Tjeerd, Lehmann, Fredrik, Hammer, Kristin, Haile, Saba, Axen, Eva, Medina, Carmen, Uppenberg, Jonas, Svensson, Stefan, Rondahl, Lena, Lundbäck, Thomas
Published in Bioorganic & medicinal chemistry letters (15.03.2009)

Get full text

Journal Article

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

by Barf, Tjeerd, Kaptein, Allard
Published in Journal of medicinal chemistry (26.07.2012)

Get full text

Journal Article

Intervention of hepatic glucose production. Small molecule regulators of potential targets for Type 2 diabetes therapy

Intervention of hepatic glucose production. Small molecule regulators of potential targets for Type 2 diabetes therapy

by Barf, Tjeerd
Published in Mini reviews in medicinal chemistry (01.10.2004)

Get more information

Journal Article

Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance

Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance

by Klüter, Sabine, Simard, Jeffrey R, Rode, Haridas B, Grütter, Christian, Pawar, Vijaykumar, Raaijmakers, Hans C.A, Barf, Tjeerd A, Rabiller, Matthias, van Otterlo, Willem A.L, Rauh, Daniel
Published in Chembiochem : a European journal of chemical biology (10.12.2010)

Get full text

Journal Article

Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target

Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target

by Lehmann, Fredik, Haile, Saba, Axen, Eva, Medina, Carmen, Uppenberg, Jonas, Svensson, Stefan, Lundbäck, Thomas, Rondahl, Lena, Barf, Tjeerd
Published in Bioorganic & medicinal chemistry letters (06.09.2004)

Get full text

Journal Article

Synthesis and Biological Activity of a Novel Class of Small Molecular Weight Peptidomimetic Competitive Inhibitors of Protein Tyrosine Phosphatase 1B

Synthesis and Biological Activity of a Novel Class of Small Molecular Weight Peptidomimetic Competitive Inhibitors of Protein Tyrosine Phosphatase 1B

by Larsen, Scott D, Barf, Tjeerd, Liljebris, Charlotta, May, Paul D, Ogg, Derek, O'Sullivan, Theresa J, Palazuk, Barbara J, Schostarez, Heinrich J, Stevens, F. Craig, Bleasdale, John E
Published in Journal of medicinal chemistry (31.01.2002)

Get full text

Journal Article

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

by Barf, Tjeerd, Covey, Todd, Izumi, Raquel, van de Kar, Bas, Gulrajani, Michael, van Lith, Bart, van Hoek, Maaike, de Zwart, Edwin, Mittag, Diana, Demont, Dennis, Verkaik, Saskia, Krantz, Fanny, Pearson, Paul G, Ulrich, Roger, Kaptein, Allard
Published in The Journal of pharmacology and experimental therapeutics (01.11.2017)

Get full text

Journal Article

Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors

Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors

by Hoogenboom, Niels, Demont, Dennis, de Zwart, Edwin, Verkaik, Saskia, Emmelot, Maaike, van de Kar, Bas, Kaptein, Allard, Barf, Tjeerd
Published in Bioorganic & medicinal chemistry letters (15.11.2021)

Get full text

Journal Article

Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors

Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors

by Podoll, Terry, Pearson, Paul G, Kaptein, Allard, Evarts, Jerry, de Bruin, Gerjan, Emmelot-van Hoek, Maaike, de Jong, Anouk, van Lith, Bart, Sun, Hao, Byard, Stephen, Fretland, Adrian, Hoogenboom, Niels, Barf, Tjeerd, Slatter, J Greg
Published in The Journal of pharmacology and experimental therapeutics (01.01.2023)

Get full text

Journal Article

Discovery of quinoline-based irreversible BTK inhibitors

Discovery of quinoline-based irreversible BTK inhibitors

by de Bruin, Gerjan, Demont, Dennis, de Zwart, Edwin, Verkaik, Saskia, Hoogenboom, Niels, van de Kar, Bas, van Lith, Bart, Emmelot- van Hoek, Maaike, Gulrajani, Michael, Covey, Todd, Kaptein, Allard, Barf, Tjeerd
Published in Bioorganic & medicinal chemistry letters (15.07.2020)

Get full text

Journal Article

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

by Kaptein, Allard, Podoll, Terry, Bruin, Gerjan de, Hoek, Maaike Emmelot-van, Jong, Anouk de, Lith, Bart van, Hoogenboom, Niels, Barf, Tjeerd, Ware, Joseph, Slatter, J. Greg
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

Abstract 4049: Preclinical pharmacology profile of GTX-0196: A novel, potent and highly selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of hematologic malignancies

by Kaptein, Allard, Lain, Sonia, Brunen, Diede, van Wezel, Edward, Barf, Tjeerd
Published in Cancer research (Chicago, Ill.) (15.06.2022)

Get full text

Journal Article

5-HT1D Receptor Agonist Properties of Novel 2-[5-[[(Trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and Their Use as Synthetic Intermediates

5-HT1D Receptor Agonist Properties of Novel 2-[5-[[(Trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and Their Use as Synthetic Intermediates

by Barf, Tjeerd A, de Boer, Peter, Wikström, Håkan, Peroutka, Stephen J, Svensson, Kjell, Ennis, Michael D, Ghazal, Nabil B, McGuire, James C, Smith, Martin W
Published in Journal of medicinal chemistry (22.11.1996)

Get full text

Journal Article

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

by Kaptein, Allard, de Bruin, Gerjan, Hoek, Maaike Emmelot-van, van de Kar, Bas, de Jong, Anouk, Gulrajani, Michael, Demont, Dennis, Covey, Todd, Mittag, Diana, Barf, Tjeerd
Published in Clinical lymphoma, myeloma and leukemia (01.09.2019)

Get full text

Journal Article

SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE

SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE

by JERRY EVARTS, TIM INGALLINERA, BLATTER FRITZ, EDWIN ARET, CECILE KREJSA, TJEERD BARF
Year of Publication 13.05.2021

Get full text

Patent

Abstract 2624: The novel Bruton's tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model

Abstract 2624: The novel Bruton's tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model

by Niemann, Carsten U., Montraveta, Arnau, Herman, Sarah E. M., Ingallinera, Tim, Barf, Tjeerd, Colomer, Dolors, Wiestner, Adrian
Published in Cancer research (Chicago, Ill.) (01.10.2014)

Get full text

Journal Article

Potential anxiolytic properties of R-(+)-8-OSO2CF3-PAT, a 5-HT1A receptor agonist

Potential anxiolytic properties of R-(+)-8-OSO2CF3-PAT, a 5-HT1A receptor agonist

by BARF, T, KORTE, S. M, KORTE-BOWS, G, SONESSON, C, DAMSMA, G, BOHUS, B, WIKSTRÖM, H
Published in European journal of pharmacology (22.02.1996)

Get full text

Journal Article

Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients

Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients

by Covey, Todd, Barf, Tjeerd, Gulrajani, Michael, Krantz, Fanny, van Lith, Bart, Bibikova, Elena, van de Kar, Bas, de Zwart, Edwin, Hamdy, Ahmed, Izumi, Raquel, Kaptein, Allard
Published in Cancer research (Chicago, Ill.) (01.08.2015)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[20]